# First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

> **NCT02644278** · PHASE1 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** VX-984 120 mg + PLD 40 mg/m^2
- **DRUG:** VX-984 240 mg + PLD 40 mg/m^2
- **DRUG:** VX-984 480 mg + PLD 40 mg/m^2
- **DRUG:** VX-984 720 mg + PLD 40 mg/m^2

## Key facts

- **NCT ID:** NCT02644278
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-29
- **Primary completion:** 2017-10-19
- **Final completion:** 2017-10-19
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02644278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02644278, "First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02644278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*